XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.2
Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenues:        
Clinical treatment programs - US $ 42 $ 30 $ 91 $ 64
Total Revenues 42 30 91 64
Costs and Expenses:        
Production costs 69 147
Research and development 2,953 2,475 5,005 3,511
General and administrative 2,550 2,181 4,841 4,253
Total Costs and Expenses 5,503 4,725 9,846 7,911
Operating loss (5,461) (4,695) (9,755) (7,847)
Gain (Loss) on investments (94) (470) 109 (1,404)
Interest and other income 318 79 517 124
Interest expense and other finance costs
(Loss) on sale of fixed assets (23)
Redeemable warrants valuation adjustment 3 34
Gain from sale of Income tax operating losses 328 232 582 422
Net Loss $ (4,909) $ (4,851) $ (8,570) $ (8,671)
Basic loss per share $ (0.10) $ (0.10) $ (0.18) $ (0.18)
Diluted loss per share $ (0.10) $ (0.10) $ (0.18) $ (0.18)
Weighted average shares outstanding basic 48,411,251 48,034,100 48,405,675 48,014,713
Weighted average shares outstanding diluted 48,411,251 48,034,100 48,405,675 48,014,713